Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Our new book is a comprehensive look at a vital part of medicines development and regulatory affairs. Grab your copy today!
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
| 03 September 2013 | By Ansis Helmanis,
Legislation has been introduced in India that would establish a new Central Drugs Authority (CDA) with overarching power to regulated drugs, devices and cosmetics.
The Drugs and Cosmetics (Amendment) Bill of 2013 was introduced on 30 August 2013 in the Rajya Sabha (Upper House of Indian Parliament) by Health and Family Welfare Minister Ghulam Nabi Azad and would replace the Drugs and Cosmetics Act of 1940.
The Central Drugs Authority would be composed of 19 members, headed by the Secretary of the Ministry of Health and Family Welfare (MHFW). It would establish regulations and norms for effective functioning of central and state drug licensing authorities and periodically assess their functioning. It would also have the authority to review, suspend or cancel any permission or license for drugs and cosmetics manufacturing.
The bill establishes centralized licensing for 17 categories of critical drugs, and includes separate chapters with regulatory frameworks governing medical devices, product exports and clinical trials, including provision for compensation for deaths or injury of a trial subjects. Penalties for violations are also set forth in the bill.
Read all Breaking News at RegLink